---
layout: default
title: Prednisolone Acetate
parent: 僅模型預測 (L5)
nav_order: 447
evidence_level: L5
indication_count: 10
---

# Prednisolone Acetate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Prednisolone Acetate: From Ocular Inflammation to Conjunctival Folliculosis

## One-Sentence Summary

Prednisolone acetate is a topical corticosteroid (ophthalmic suspension), generally used for steroid-responsive ocular inflammatory conditions, though this evidence pack does not contain a documented original indication or licensing text. The TxGNN model's top-ranked prediction for this drug is **Conjunctival Folliculosis** (score 99.74%), but this specific pairing currently has **0 clinical trials** and **0 publications** supporting it — the evidence level is the lowest possible tier (L5, model prediction only).

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in evidence pack (no license records); prednisolone acetate ophthalmic suspension is generally known for steroid-responsive ocular inflammation |
| Predicted New Indication | Conjunctival Folliculosis |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| Canada Market Status | Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this evidence pack). Based on known pharmacology, prednisolone acetate is a corticosteroid ester formulated as a topical ophthalmic suspension; corticosteroids broadly suppress inflammatory mediators (cytokines, prostaglandins) and reduce leukocyte infiltration at the site of application. This general anti-inflammatory mechanism is likely why the TxGNN model links prednisolone acetate to a wide range of conjunctival and inflammatory eye conditions — ten such conditions appear in this candidate set, ranging in TxGNN score from 99.74% down to 99.44%.

For the specific top-ranked prediction evaluated here — **conjunctival folliculosis** — the rationale is notably weak. Conjunctival folliculosis is typically a benign, self-limiting lymphoid tissue reaction that resolves without pharmacological intervention, and there is no clinical trial or literature evidence in this pack connecting prednisolone acetate to this condition specifically. In other words, the prediction is a pure knowledge-graph association without any observed clinical or mechanistic corroboration.

It is worth noting that other indications within this same candidate set have materially stronger support: **vernal conjunctivitis** (rank 9, L2, 1 clinical trial + 19 publications, "Proceed with Guardrails") and **papillary conjunctivitis** (rank 5, L2, 2 clinical trials + 6 publications, "Proceed with Guardrails") are both Th2/allergic-inflammation-mediated conditions where topical corticosteroids are an established treatment class, and where same-class comparator data (loteprednol etabonate) exists. These may represent more actionable repurposing directions than conjunctival folliculosis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

Prednisolone acetate currently has no market authorization (DIN) records in Canada (market status: **Not Marketed**, 0 total licenses on file).

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: This evidence pack flags a **Blocking** data gap (DG001) for TFDA label warnings/contraindications — this must be resolved before any safety-stage (S1) evaluation can proceed, regardless of indication.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (conjunctival folliculosis) is supported only by the TxGNN model score with zero clinical trials or literature (Evidence Level L5), and the target condition is typically self-resolving, offering limited clinical rationale for drug intervention. Separately, a Blocking data gap on TFDA safety labeling prevents this candidate from advancing to a safety evaluation stage regardless of indication-level evidence.

**To proceed, the following is needed:**
- TFDA package insert warnings/contraindications (DG001 — Blocking; source: TFDA official site, PDF label parsing)
- Drug mechanism of action detail from DrugBank (DG002 — High priority)
- If pursuing conjunctival folliculosis specifically, primary clinical or preclinical evidence is needed, as none currently exists
- Consider prioritizing evaluation of **vernal conjunctivitis** or **papillary conjunctivitis** instead — both are ranked lower by TxGNN score within this same candidate set but carry materially stronger evidence (L2, "Proceed with Guardrails") and may be more efficient use of further review resources
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

